The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Stephen Nolan, a BBC Radio Ulster and Radio 5 Live presenter, has openly discussed his struggles with weight for many years. Recently, he shared that he's using weight loss injections in addition to diet and exercise. Nolan has already lost a significant amount of weight.
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
The Cleveland Clinic is utilizing an AI-powered approach to reverse type 2 diabetes. This innovative method focuses on creating a 'digital twin' of a patient's metabolism, leading to significant improvements in health markers and a reduction in medication dependence.
The Delhi High Court has upheld a previous ruling that allows Dr. Reddy's Laboratories to manufacture Semaglutide for export. This decision comes amid an ongoing patent dispute with Novo Nordisk, who claims Dr. Reddy's infringed on their Semaglutide patent.
Vikrant Shrotriya of Novo Nordisk India details Ozempic's launch in India, emphasizing stable supply and accessibility. He addresses patent expiry and competition, focusing on broader patient access and combating obesity.
The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.
New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.
A new weight loss drug, retatrutide, is showing promise by mimicking three hunger-regulating hormones. Clinical trial data indicates significant weight loss and reduced knee pain.
A novel drug candidate from Eli Lilly, targeting three metabolic pathways, has shown impressive weight loss results in a late-stage clinical trial. The study revealed an average weight loss of 28.7% among participants. However, the trial also reported a notable rate of treatment discontinuation.
